These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 39032510)

  • 1. Patients with Cushing's syndrome suffer from provoked venous thromboembolism and are anticoagulated in various patterns.
    Bryk-Wiązania AH; Minasyan M; Hubalewska-Dydejczyk A; Gilis-Januszewska A
    Endocr Connect; 2024 Sep; 13(9):. PubMed ID: 39032510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High prevalence of venous thrombotic events in Cushing's syndrome: data from ERCUSYN and details in relation to surgery.
    Isand K; Feelders R; Brue T; Toth M; Deutschbein T; Reincke M; Kršek M; Santos A; Demtröder F; Chabre O; Strasburger CJ; Aulinas Maso A; Volke V; Pereira AM; Lohmann R; Gich Saladich I; ; Webb SM; Wass J; Valassi E
    Eur J Endocrinol; 2024 Jan; 190(1):75-85. PubMed ID: 38146835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The thrombotic risk in Cushing's syndrome-questions, answers, and the algorithm to consider in its assessment: part I-thrombotic risk not related to surgery.
    Bryk-Wiązania AH; Minasyan M; Świątkowska-Stodulska R; Undas A; Hubalewska-Dydejczyk A; Webb SM; Valassi E; Gilis-Januszewska A
    Front Endocrinol (Lausanne); 2024; 15():1350010. PubMed ID: 38529392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Do women with venous thromboembolism bleed more than men during anticoagulation? Data from the real-life, prospective START-Register.
    Palareti G; Legnani C; Antonucci E; Cosmi B; Falanga A; Poli D; Mastroiacovo D; Pengo V; Ageno W; Testa S
    Ther Adv Drug Saf; 2021; 12():20420986211062965. PubMed ID: 34987749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A venous thromboembolism risk assessment model for patients with Cushing's syndrome.
    Zilio M; Mazzai L; Sartori MT; Barbot M; Ceccato F; Daidone V; Casonato A; Saggiorato G; Noventa F; Trementino L; Prandoni P; Boscaro M; Arnaldi G; Scaroni C
    Endocrine; 2016 May; 52(2):322-32. PubMed ID: 26113424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current clinical practice for thromboprophylaxis management in patients with Cushing's syndrome across reference centers of the European Reference Network on Rare Endocrine Conditions (Endo-ERN).
    van Haalen FM; Kaya M; Pelsma ICM; Dekkers OM; Biermasz NR; Cannegieter SC; Huisman MV; van Vlijmen BJM; Feelders RA; Klok FA; Pereira AM;
    Orphanet J Rare Dis; 2022 May; 17(1):178. PubMed ID: 35505430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CUSHING'S SYNDROME, A RISK FACTOR FOR VENOUS THROMBOEMBOLISM IS A CANDIDATE FOR GUIDELINES.
    Koraćević G; Stojanović M; Petrović S; Simić D; Sakač D; Vlajković M; Stevic M; Kocić M; Đorđević M; Koraćević M
    Acta Endocrinol (Buchar); 2020; 16(2):123-128. PubMed ID: 33029226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypercoagulability in Cushing's syndrome: incidence, pathogenesis and need for thromboprophylaxis protocols.
    Feelders RA; Nieman LK
    Pituitary; 2022 Oct; 25(5):746-749. PubMed ID: 35881275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of venous thromboembolism in patients with Cushing's syndrome: a multicenter cohort study.
    Stuijver DJ; van Zaane B; Feelders RA; Debeij J; Cannegieter SC; Hermus AR; van den Berg G; Pereira AM; de Herder WW; Wagenmakers MA; Kerstens MN; Zelissen PM; Fliers E; Schaper N; Drent ML; Dekkers OM; Gerdes VE
    J Clin Endocrinol Metab; 2011 Nov; 96(11):3525-32. PubMed ID: 21880802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic treatments for the prevention of venous thrombo-embolic events in paediatric cancer patients with tunnelled central venous catheters.
    Schoot RA; Kremer LC; van de Wetering MD; van Ommen CH
    Cochrane Database Syst Rev; 2013 Sep; (9):CD009160. PubMed ID: 24026801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct Oral Anticoagulants in Patients With Inherited Thrombophilia and Venous Thromboembolism: A Prospective Cohort Study.
    Campello E; Spiezia L; Simion C; Tormene D; Camporese G; Dalla Valle F; Poretto A; Bulato C; Gavasso S; Radu CM; Simioni P
    J Am Heart Assoc; 2020 Dec; 9(23):e018917. PubMed ID: 33222589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Provoked versus unprovoked venous thromboembolism: Findings from GARFIELD-VTE.
    Ageno W; Farjat A; Haas S; Weitz JI; Goldhaber SZ; Turpie AGG; Goto S; Angchaisuksiri P; Dalsgaard Nielsen J; Kayani G; Schellong S; Bounameaux H; Mantovani LG; Prandoni P; Kakkar AK
    Res Pract Thromb Haemost; 2021 Feb; 5(2):326-341. PubMed ID: 33733032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair.
    Forster R; Stewart M
    Cochrane Database Syst Rev; 2016 Mar; 3(3):CD004179. PubMed ID: 27027384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
    Bates SM; Greer IA; Pabinger I; Sofaer S; Hirsh J
    Chest; 2008 Jun; 133(6 Suppl):844S-886S. PubMed ID: 18574280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thirteen-year trend in the persistence with vitamin K antagonists for venous thromboembolism in the UK: a cohort study.
    Martinez C; Katholing A; Folkerts K; Rietbrock S
    Curr Med Res Opin; 2018 Nov; 34(11):1985-1990. PubMed ID: 29798688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Global Anticoagulant Registry in the Field - Venous Thromboembolism (GARFIELD-VTE). Rationale and design.
    Weitz JI; Haas S; Ageno W; Angchaisuksiri P; Bounameaux H; Nielsen JD; Goldhaber SZ; Goto S; Kayani G; Mantovani L; Prandoni P; Schellong S; Turpie AG; Kakkar AK
    Thromb Haemost; 2016 Nov; 116(6):1172-1179. PubMed ID: 27656711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between anticoagulant treatment duration and risk of venous thromboembolism recurrence and bleeding in clinical practice.
    Kaatz S; Fu AC; AbuDagga A; LaMori J; Bookhart BK; Damaraju CV; Tan H; Schein J; Nutescu E
    Thromb Res; 2014 Oct; 134(4):807-13. PubMed ID: 25127013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Empirical systemic anticoagulation is associated with decreased venous thromboembolism in critically ill influenza A H1N1 acute respiratory distress syndrome patients.
    Obi AT; Tignanelli CJ; Jacobs BN; Arya S; Park PK; Wakefield TW; Henke PK; Napolitano LM
    J Vasc Surg Venous Lymphat Disord; 2019 May; 7(3):317-324. PubMed ID: 30477976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cushing's syndrome in the elderly: data from the European Registry on Cushing's syndrome.
    Amodru V; Ferriere A; Tabarin A; Castinetti F; Tsagarakis S; Toth M; Feelders RA; Webb SM; Reincke M; Netea-Maier R; Kastelan D; Elenkova A; Maiter D; Ragnarsson O; Santos A; Valassi E;
    Eur J Endocrinol; 2023 Apr; 188(4):395-406. PubMed ID: 36749009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk stratification for predicting recurrent venous thromboembolism after discontinuation of anticoagulation: a
    Le Mao R; Orione C; de Moreuil C; Tromeur C; Hoffmann C; Fauché A; Robin P; Didier R; Guegan M; Jiménez D; Le Moigne E; Leroyer C; Lacut K; Couturaud F
    Eur Respir J; 2022 Sep; 60(3):. PubMed ID: 35210315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.